Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 10

Results For "Dash"

1818 News Found

BioNTech maps pivotal oncology milestones for 2026
News | January 15, 2026

BioNTech maps pivotal oncology milestones for 2026

BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company


CARsgen and Dispatch Bio launch groundbreaking CAR T collaboration in China
Clinical Trials | January 15, 2026

CARsgen and Dispatch Bio launch groundbreaking CAR T collaboration in China

CARsgen is working to transform outcomes for patients with solid tumors by advancing the potential of CAR T technologies


Boehringer Ingelheim and Jazz Pharma team up on novel HER2-positive breast cancer therapy
Clinical Trials | January 15, 2026

Boehringer Ingelheim and Jazz Pharma team up on novel HER2-positive breast cancer therapy

The partnership will launch a Phase 1b cohort within Boehringer’s ongoing Beamion-BCGC1 trial


Merck scores FDA nod for TGT drug Pimicotinib, promising new hope for patients
Drug Approval | January 14, 2026

Merck scores FDA nod for TGT drug Pimicotinib, promising new hope for patients

The trial also revealed statistically significant and clinically meaningful gains in key patient-reported outcomes


Avista Therapeutics unveils AI-powered expansion of gene therapy platform
R&D | January 14, 2026

Avista Therapeutics unveils AI-powered expansion of gene therapy platform

The company is rolling out ARTEMIS, a next-generation AI platform for capsid design


GRIN Therapeutics launches global Phase 3 trial for groundbreaking GRIN-NDD therapy
Clinical Trials | January 14, 2026

GRIN Therapeutics launches global Phase 3 trial for groundbreaking GRIN-NDD therapy

GRIN-NDD is one of the most complex neurodevelopmental disorders with limited treatment options today


Bayer acquires Attralus’ cutting-edge cardiac amyloidosis imaging agents
News | January 14, 2026

Bayer acquires Attralus’ cutting-edge cardiac amyloidosis imaging agents

The acquisition of AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) positions Bayer at the forefront of cardiac amyloidosis diagnostics